艾伯维公司(ABBV)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

ABBV 艾伯维公司

休市中 02-13 16:00:00 EST

231.50

+4.00

+1.76%

盘后232.22

+0.72+0.31%

19:58 EST

最高234.74	最低228.00	成交量825.25万
今开228.42	昨收227.50	日振幅2.96%
总市值4,091亿	流通市值4,081亿	总股本17.67亿
成交额19.15亿	换手率0.47%	流通股本17.63亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"ABBV","market":"US","secType":"STK","nameCN":"艾伯维公司","latestPrice":231.5,"timestamp":1771016400000,"preClose":227.5,"halted":0,"volume":8252480,"hourTrading":{"tag":"盘后","latestPrice":232.2198,"preClose":231.5,"latestTime":"19:58 EST","volume":1096037,"amount":253732593.1594,"timestamp":1771030724869,"change":0.7198,"changeRate":0.003109,"amplitude":0.004103},"delay":0,"changeRate":0.017582417582417582,"floatShares":1762950764,"shares":1767384632,"eps":2.36,"marketStatus":"休市中","change":4,"latestTime":"02-13 16:00:00 EST","open":228.42,"high":234.74,"low":228,"amount":1914877978.4415998,"amplitude":0.029626,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":2.36,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1771318800000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"NYSE","adjPreClose":227.5,"dividendRate":0.028726,"preHourTrading":{"tag":"盘前","latestPrice":227.64,"preClose":227.5,"latestTime":"09:26 EST","volume":1429,"amount":325296.05955,"timestamp":1770992794983,"change":0.14,"changeRate":0.000615,"amplitude":0.00633},"postHourTrading":{"tag":"盘后","latestPrice":232.2198,"preClose":231.5,"latestTime":"19:58 EST","volume":1096037,"amount":253732593.1594,"timestamp":1771030724869,"change":0.7198,"changeRate":0.003109,"amplitude":0.004103},"volumeRatio":1.1569806229418171,"impliedVol":0.2868,"impliedVolPercentile":0.5498},"requestUrl":"/m/hq/s/abbv","defaultTab":"news","newsList":[{"id":"2609558780","title":"2025Q4| 艾伯维免疫明星表现不一：乌帕替尼强势增长，利生奇珠单抗未达预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2609558780","media":"Minhua笔记","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609558780?lang=zh_cn&edition=full","pubTime":"2026-02-05 13:57","pubTimestamp":1770271040,"startTime":"0","endTime":"0","summary":"2月4日，艾伯维公布2025年第四季度及全年业绩，营收和盈利均超预期。公司股价当天下跌约4%，投资者对Humira衰退期公司增长仍依赖该药表示担忧。艾伯维第四季度销售额超出预期约2亿美元，这主要得益于其重磅药物Humira的出色表现，而其后续免疫学药物Rinvoq强势增长，但Skyrizi的业绩则低于预期。Skyrizi 增长 32.5%，达到 50 亿美元，超过预期的 49 亿美元；Rinvoq 增长 29.5%，达到 23.7 亿美元，但略低于预期。其中，Skyrizi和Rinvoq预计分别贡献约215亿美元和101亿美元的收入。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260205152126a47f0cd8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260205152126a47f0cd8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ABBV","LU0256863811.USD","LU2347655156.SGD","LU0310800379.SGD","IE00BJJMRZ35.SGD","LU2237443622.USD","IE00BGHQF631.EUR","IE0002270589.USD","LU0861579265.USD","LU2129689605.HKD","LU1430594728.SGD","LU1929549753.HKD","BK4566","IE00B19Z3B42.SGD","IE0004445239.USD","IE00B3PB1722.GBP","LU0912757837.SGD","LU0820561818.USD","LU2468319806.SGD","BK4585","SG9999001440.SGD","LU0158827948.USD","LU0320765646.SGD","LU1037948541.HKD","IE00BFTCPJ56.SGD","SG9999015952.SGD","LU0203345920.USD","LU0211327993.USD","LU2237443549.SGD","IE00BBT3K403.USD","LU2089283258.USD","LU0256863902.USD","LU2237443978.SGD","LU0289739343.SGD","LU0965509283.SGD","LU2112291526.USD","SG9999015978.USD","LU0289961442.SGD","LU0511384066.AUD","SG9999003800.SGD","LU1551013342.USD","LU1989771016.USD","LU2237443895.HKD","LU2129689514.USD","BK4559","IE00BSNM7G36.USD","LU1267930573.SGD","LU0124676726.USD","LU1718418525.SGD","LU1585245621.USD"],"gpt_icon":0},{"id":"1152082663","title":"艾伯维高管预计：2026年及未来数年Skyrizi与Rinvoq将持续面临个位数低价压力","url":"https://stock-news.laohu8.com/highlight/detail?id=1152082663","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1152082663?lang=zh_cn&edition=full","pubTime":"2026-02-04 23:32","pubTimestamp":1770219134,"startTime":"0","endTime":"0","summary":"艾伯维公司高管近日表示，旗下明星药物Skyrizi（瑞莎珠单抗）与Rinvoq（乌帕替尼）在2026年及后续几年中，预计将持续承受较低的个位数百分比定价阻力。这一预测反映出生物制药行业在医保控费与市场竞争双重压力下的新常态。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4550","LU0158827948.USD","LU0511384066.AUD","LU1162221912.USD","LU0985320562.USD","BK4588","LU0965509283.SGD","LU0820561909.HKD","LU1839511570.USD","LU0795875169.SGD","IE00BLSP4239.USD","LU2129689431.USD","LU2347655156.SGD","LU0949170772.SGD","SG9999011175.SGD","LU0256863902.USD","LU0128525929.USD","LU1989772923.USD","LU2129689605.HKD","LU0708994859.HKD","LU2129689514.USD","LU0211328371.USD","IE00B19Z3581.USD","LU0122379950.USD","LU0472753341.HKD","LU0545039389.USD","IE00BBT3K403.USD","SG9999003800.SGD","LU0912757837.SGD","LU0943347566.SGD","IE00B19Z3B42.SGD","IE0002141913.USD","BK4566","IE00BSNM7G36.USD","LU0689472784.USD","SG9999015986.USD","LU1244550221.USD","LU1585245621.USD","LU2023251221.USD","IE00B42XCP33.USD","LU0965509101.SGD","BK4581","LU0203347892.USD","BK4533","LU0456855351.SGD","LU1003077747.HKD","LU0289739699.SGD","LU1496350171.SGD","BK4139","LU1496350502.SGD","LU0795875086.SGD","BK4534","LU1037948541.HKD","LU1551013425.SGD","LU0057025933.USD","LU0098860793.USD","IE00BN8TJ469.HKD","LU2237443465.HKD","LU0417517546.SGD","IE00BVYPNV92.GBP","LU0689626769.HKD","LU2237443549.SGD","IE00BGHQF631.EUR","LU2237443382.USD","SG9999015978.USD","LU2112291526.USD","LU0211327993.USD","LU1934455194.USD","IE0009355771.USD","IE0004445239.USD","BK4559","LU0234572021.USD","LU0114720955.EUR","LU1093756325.SGD","LU1430594728.SGD","IE00B3PB1722.GBP","LU0310800379.SGD","LU0069063385.USD","LU1057294990.SGD","IE00BJT1NW94.SGD","IE00BLSP4452.SGD","LU0124676726.USD","LU1934455277.USD","LU1023059063.AUD","LU0965509010.AUD","LU2089283258.USD","LU0234570918.USD","LU1551013342.USD","LU0738911758.USD","IE00BFTCPJ56.SGD","LU0256863811.USD","LU0882574055.USD","LU1934455863.HKD","LU0289739343.SGD","LU1989772840.SGD","IE00BDGV0183.EUR","LU0198837287.USD","LU0320765646.SGD","IE00BJJMRZ35.SGD","LU0661504455.SGD","SG9999015952.SGD","LU1291159041.SGD","LU2089284900.SGD","LU1983299246.USD","LU2237443895.HKD","LU1989771016.USD","IE0002270589.USD","LU2237443622.USD","IE00BVYPNW00.USD","LU1037948897.HKD","IE00B4R5TH58.HKD","LU0310799852.SGD","LU1732800096.USD","IE00B2B36J28.USD","LU1929549753.HKD","LU1244550494.USD","LU1718418525.SGD","LU2237443978.SGD","SG9999001440.SGD","LU1074936037.SGD","LU2133065610.SGD","ABBV","LU0029864427.USD","LU0170899867.USD","LU0553294199.USD","LU1093756168.USD","LU0203345920.USD","LU2087621335.USD","BK4585","LU2468319806.SGD","LU0289961442.SGD","LU2089984988.USD","LU1244550577.SGD","LU1732799900.SGD","LU0058720904.USD","LU0965508806.USD","LU1061106388.HKD","SG9999015945.SGD","LU0820561818.USD","LU1267930573.SGD","LU1267930490.SGD","LU0432979614.USD","LU0861579265.USD"],"gpt_icon":0},{"id":"1128110797","title":"艾伯维高管称公司资金充足，可同时布局早期及后期并购机遇——电话会议透露","url":"https://stock-news.laohu8.com/highlight/detail?id=1128110797","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1128110797?lang=zh_cn&edition=full","pubTime":"2026-02-04 23:31","pubTimestamp":1770219079,"startTime":"0","endTime":"0","summary":"艾伯维公司高管在最新电话会议中表示，公司目前拥有充足的资金实力，能够同步推进早期阶段与成熟阶段的并购机会。这一表态凸显了艾伯维在生物医药领域持续扩张的战略布局。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1839511570.USD","LU1244550221.USD","LU0820561818.USD","LU0058720904.USD","LU0256863811.USD","LU0553294199.USD","LU1291159041.SGD","IE00BLSP4452.SGD","LU1023059063.AUD","LU0965508806.USD","LU0203347892.USD","LU1037948897.HKD","IE00BLSP4239.USD","LU1061106388.HKD","LU1162221912.USD","LU0211327993.USD","LU1551013342.USD","LU1057294990.SGD","LU1496350502.SGD","LU1934455194.USD","LU0472753341.HKD","LU2129689605.HKD","LU2087621335.USD","LU1093756325.SGD","LU1718418525.SGD","SG9999015952.SGD","IE00B19Z3581.USD","IE00BVYPNW00.USD","SG9999015978.USD","LU1934455863.HKD","LU0170899867.USD","LU2129689514.USD","LU2237443382.USD","LU2023251221.USD","LU0057025933.USD","SG9999001440.SGD","LU0949170772.SGD","IE00B19Z3B42.SGD","LU1430594728.SGD","IE00BJT1NW94.SGD","SG9999011175.SGD","LU0943347566.SGD","LU0289739343.SGD","LU0861579265.USD","LU1983299246.USD","LU0820561909.HKD","LU0234570918.USD","LU1074936037.SGD","IE0004445239.USD","LU0128525929.USD","IE00B2B36J28.USD","IE00BSNM7G36.USD","LU2237443978.SGD","LU0158827948.USD","LU0545039389.USD","LU1037948541.HKD","LU1732800096.USD","LU1989772923.USD","SG9999015945.SGD","IE00B4R5TH58.HKD","LU1585245621.USD","LU0289739699.SGD","LU0114720955.EUR","LU2347655156.SGD","LU1551013425.SGD","IE0009355771.USD","LU1093756168.USD","LU0069063385.USD","LU0122379950.USD","LU0795875169.SGD","LU1267930573.SGD","IE00B3PB1722.GBP","LU1732799900.SGD","LU0882574055.USD","LU2237443549.SGD","LU1003077747.HKD","LU0289961442.SGD","BK4581","LU1244550577.SGD","IE00BN8TJ469.HKD","SG9999003800.SGD","LU0738911758.USD","LU2089283258.USD","LU0912757837.SGD","LU1929549753.HKD","BK4534","IE00BBT3K403.USD","LU0432979614.USD","LU2089984988.USD","LU0310800379.SGD","LU2237443895.HKD","LU2112291526.USD","LU0310799852.SGD","LU0203345920.USD","LU1989772840.SGD","BK4559","BK4139","IE00BVYPNV92.GBP","LU0708994859.HKD","BK4550","LU0795875086.SGD","IE00BFTCPJ56.SGD","ABBV","LU2133065610.SGD","LU1267930490.SGD","BK4533","LU0211328371.USD","LU0029864427.USD","LU0689626769.HKD","LU0965509101.SGD","LU2089284900.SGD","LU2237443465.HKD","IE0002270589.USD","SG9999015986.USD","LU0256863902.USD","LU2129689431.USD","BK4585","LU0198837287.USD","LU1934455277.USD","LU0124676726.USD","LU0965509283.SGD","BK4566","LU0511384066.AUD","IE00BJJMRZ35.SGD","IE0002141913.USD","LU0965509010.AUD","LU0417517546.SGD","LU1496350171.SGD","LU1244550494.USD","LU0234572021.USD","IE00BDGV0183.EUR","BK4588","LU0689472784.USD","LU1989771016.USD","LU0098860793.USD","LU2468319806.SGD","IE00B42XCP33.USD","LU0985320562.USD","LU0320765646.SGD","LU0456855351.SGD","LU2237443622.USD","LU0661504455.SGD","IE00BGHQF631.EUR"],"gpt_icon":0},{"id":"1138286335","title":"艾伯维高管称潜在交易不限于早期阶段，聚焦核心领域：免疫学、神经科学、肿瘤学及肥胖症布局","url":"https://stock-news.laohu8.com/highlight/detail?id=1138286335","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1138286335?lang=zh_cn&edition=full","pubTime":"2026-02-04 23:30","pubTimestamp":1770219013,"startTime":"0","endTime":"0","summary":"艾伯维公司高管近日表示，公司在寻求潜在交易时不会局限于早期阶段项目，而是将战略重点集中于核心业务领域。这些关键领域包括免疫学、神经科学、肿瘤学，以及正在积极拓展的肥胖症治疗方向。公司旨在通过多元化的合作方式强化产品管线，推动长期增长。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0820561909.HKD","SG9999011175.SGD","LU0198837287.USD","LU0456855351.SGD","LU0203345920.USD","LU0256863811.USD","LU0310799852.SGD","LU0203347892.USD","LU2133065610.SGD","IE00B4R5TH58.HKD","LU1003077747.HKD","LU1496350171.SGD","LU0158827948.USD","LU0738911758.USD","LU0128525929.USD","LU0124676726.USD","LU0965509010.AUD","LU0882574055.USD","IE00BN8TJ469.HKD","LU0098860793.USD","LU0211328371.USD","LU0985320562.USD","LU0861579265.USD","LU1023059063.AUD","LU1057294990.SGD","LU0320765646.SGD","LU1061106388.HKD","LU0472753341.HKD","IE00B42XCP33.USD","LU2112291526.USD","LU0545039389.USD","BK4581","LU0234572021.USD","LU1037948897.HKD","LU0689472784.USD","LU2089284900.SGD","LU2023251221.USD","SG9999015978.USD","LU2087621335.USD","LU1037948541.HKD","LU1839511570.USD","LU0708994859.HKD","LU0432979614.USD","LU0795875169.SGD","LU0114720955.EUR","IE00BVYPNV92.GBP","BK4588","LU1267930490.SGD","LU0058720904.USD","IE00BLSP4239.USD","LU0689626769.HKD","LU1551013342.USD","ABBV","IE00BBT3K403.USD","LU0795875086.SGD","LU0234570918.USD","LU1074936037.SGD","IE00BDGV0183.EUR","LU2129689431.USD","LU1244550494.USD","LU2347655156.SGD","BK4559","LU2237443895.HKD","IE00B2B36J28.USD","LU0943347566.SGD","LU2089283258.USD","SG9999015945.SGD","LU2237443978.SGD","LU0289739343.SGD","LU0069063385.USD","LU0912757837.SGD","SG9999001440.SGD","IE00B19Z3581.USD","LU1983299246.USD","LU0965509283.SGD","LU0170899867.USD","LU0289739699.SGD","LU1093756168.USD","BK4534","LU0965509101.SGD","LU1244550577.SGD","IE0002270589.USD","IE00BJT1NW94.SGD","LU1934455277.USD","LU1718418525.SGD","LU0310800379.SGD","LU0256863902.USD","LU1291159041.SGD","LU1430594728.SGD","LU0289961442.SGD","LU0553294199.USD","LU0511384066.AUD","LU2237443465.HKD","LU0122379950.USD","LU1585245621.USD","IE00BVYPNW00.USD","LU1496350502.SGD","LU2468319806.SGD","LU2089984988.USD","SG9999015986.USD","BK4550","LU0029864427.USD","LU2237443382.USD","LU1989772923.USD","LU0965508806.USD","LU2237443549.SGD","LU1929549753.HKD","SG9999003800.SGD","IE0009355771.USD","LU0057025933.USD","LU1989772840.SGD","IE00BSNM7G36.USD","LU2129689514.USD","LU1162221912.USD","IE00BLSP4452.SGD","LU1267930573.SGD","LU1551013425.SGD","BK4139","LU1244550221.USD","LU1732800096.USD","LU0820561818.USD","LU0211327993.USD","IE00B3PB1722.GBP","LU2129689605.HKD","LU0949170772.SGD","LU1989771016.USD","IE00B19Z3B42.SGD","BK4585","IE0004445239.USD","LU0661504455.SGD","LU1093756325.SGD","BK4566","IE00BJJMRZ35.SGD","IE00BGHQF631.EUR","LU1732799900.SGD","SG9999015952.SGD","IE0002141913.USD","LU1934455194.USD","LU0417517546.SGD","BK4533","IE00BFTCPJ56.SGD","LU1934455863.HKD","LU2237443622.USD"],"gpt_icon":0},{"id":"1186940641","title":"异动解读 | 艾伯维盘中大跌7.25%，营收结构担忧、医美业务承压及一次性费用拖累股价","url":"https://stock-news.laohu8.com/highlight/detail?id=1186940641","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1186940641?lang=zh_cn&edition=full","pubTime":"2026-02-04 22:41","pubTimestamp":1770216062,"startTime":"0","endTime":"0","summary":"艾伯维（ABBV）今日盘中股价大幅下跌7.25%，引发了市场广泛关注。消息面上，尽管公司预测2026年利润高于预期，但分析师指出其营收增长主要依赖传统药物Humira，而该药销售额正受到仿制药侵蚀，引发了市场对营收结构可持续性的担忧。同时，公司高管预计2026年医美业务增长仍将面临挑战，需通过投资刺激渗透率偏低的市场。此外，公司最新公布的第四季度业绩受到收购相关无形资产研发及里程碑费用的显著拖累，这些一次性支出对每股收益造成了0.71美元的负面影响。市场对上述因素的叠加反应，共同导致了此次股价的大幅下挫。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["ABBV"],"gpt_icon":0},{"id":"1135576917","title":"艾伯维高管预计：2026年Skyrizi收入将达215亿美元，Rinvoq收入将达101亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1135576917","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1135576917?lang=zh_cn&edition=full","pubTime":"2026-02-04 22:36","pubTimestamp":1770215794,"startTime":"0","endTime":"0","summary":"艾伯维公司高管近日透露，预计到2026年，其明星产品Skyrizi的年收入将攀升至215亿美元，而同为重磅药物的Rinvoq也将实现101亿美元的营收目标。这一预测凸显了公司对这两款免疫疾病治疗药物市场前景的强烈信心。\n随着全球自身免疫疾病患者群体的持续扩大，Skyrizi和Rinvoq凭借卓越的临床疗效，正逐步成为细分领域的领军产品。分析指出，若能达到预期目标，这两款药物将共同构筑艾伯维未来业绩增长的双引擎，有效抵消明星修美乐专利到期后带来的收入压力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2087621335.USD","IE00B2B36J28.USD","IE0009355771.USD","LU2129689431.USD","LU1267930573.SGD","LU1839511570.USD","LU0256863902.USD","SG9999003800.SGD","SG9999015952.SGD","IE00BLSP4452.SGD","LU0289739343.SGD","LU0965509010.AUD","LU0912757837.SGD","LU1496350502.SGD","LU1718418525.SGD","BK4581","LU0689472784.USD","LU0203347892.USD","LU2237443465.HKD","LU0069063385.USD","LU0128525929.USD","IE00B3PB1722.GBP","BK4533","LU0310800379.SGD","LU1551013425.SGD","LU1244550577.SGD","IE0004445239.USD","IE00BFTCPJ56.SGD","LU1037948897.HKD","LU1244550221.USD","LU2237443622.USD","LU2023251221.USD","BK4550","IE00BN8TJ469.HKD","IE0002270589.USD","LU1093756325.SGD","IE00B19Z3B42.SGD","BK4559","LU0417517546.SGD","LU1585245621.USD","LU0553294199.USD","LU0114720955.EUR","LU0211327993.USD","LU1934455194.USD","LU0795875169.SGD","LU1037948541.HKD","LU2089284900.SGD","LU2112291526.USD","IE00BJJMRZ35.SGD","LU0256863811.USD","LU0861579265.USD","LU0289961442.SGD","LU1061106388.HKD","LU0965509283.SGD","LU0965508806.USD","LU1057294990.SGD","IE00B19Z3581.USD","LU0985320562.USD","IE00BBT3K403.USD","SG9999015945.SGD","LU0124676726.USD","BK4139","LU0965509101.SGD","LU2237443549.SGD","LU2237443895.HKD","LU2237443978.SGD","LU1732800096.USD","LU0738911758.USD","SG9999011175.SGD","LU0882574055.USD","LU1934455863.HKD","BK4534","LU1093756168.USD","LU0708994859.HKD","LU0234572021.USD","IE00BLSP4239.USD","LU1291159041.SGD","LU0949170772.SGD","LU0545039389.USD","LU1551013342.USD","LU0472753341.HKD","LU2089984988.USD","LU2129689605.HKD","LU0198837287.USD","LU1003077747.HKD","IE00BVYPNV92.GBP","LU2347655156.SGD","LU0795875086.SGD","LU1983299246.USD","LU1934455277.USD","LU0234570918.USD","LU0820561909.HKD","IE00B42XCP33.USD","SG9999015986.USD","LU1074936037.SGD","LU1430594728.SGD","LU0456855351.SGD","LU0820561818.USD","LU2468319806.SGD","LU0432979614.USD","LU0203345920.USD","LU1496350171.SGD","LU1023059063.AUD","LU0320765646.SGD","LU0057025933.USD","BK4588","IE00BSNM7G36.USD","LU1244550494.USD","LU0211328371.USD","IE00B4R5TH58.HKD","LU0170899867.USD","BK4585","LU1929549753.HKD","LU1989771016.USD","SG9999001440.SGD","LU2237443382.USD","LU1989772923.USD","LU0029864427.USD","LU2089283258.USD","LU0289739699.SGD","BK4566","IE00BVYPNW00.USD","LU0058720904.USD","LU0158827948.USD","LU0098860793.USD","LU2133065610.SGD","LU0310799852.SGD","LU2129689514.USD","IE00BJT1NW94.SGD","IE0002141913.USD","LU1267930490.SGD","SG9999015978.USD","LU0689626769.HKD","LU1162221912.USD","LU0122379950.USD","LU0943347566.SGD","ABBV","IE00BGHQF631.EUR","LU0511384066.AUD","LU1989772840.SGD","IE00BDGV0183.EUR","LU0661504455.SGD","LU1732799900.SGD"],"gpt_icon":0},{"id":"1170942267","title":"异动解读 | 艾伯维盘前大跌6.5%，营收增长依赖传统药物及医美业务承压拖累股价","url":"https://stock-news.laohu8.com/highlight/detail?id=1170942267","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1170942267?lang=zh_cn&edition=full","pubTime":"2026-02-04 22:27","pubTimestamp":1770215246,"startTime":"0","endTime":"0","summary":"艾伯维公司（ABBV）今日盘前股价大幅下跌6.50%，引发了市场广泛关注。消息面上，尽管公司预测2026年利润高于预期，但分析师指出其营收增长主要依赖传统药物Humira，而该药销售额正受到仿制药侵蚀，引发市场担忧。同时，公司高管预计2026年医美业务增长仍将面临挑战，需通过投资刺激渗透率偏低的市场。此外，公司第四季度业绩受到收购相关无形资产研发及里程碑费用的显著拖累，对每股收益造成0.71美元的负面影响。综合来看，市场对艾伯维营收结构可持续性的疑虑、部分业务增长压力以及短期业绩受一次性费用拖累，共同导致了此次股价的大幅下跌。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["ABBV"],"gpt_icon":0},{"id":"1154893154","title":"艾伯维高管预计2026年医美业务增长仍将承压 将重点投资刺激渗透率偏低市场","url":"https://stock-news.laohu8.com/highlight/detail?id=1154893154","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1154893154?lang=zh_cn&edition=full","pubTime":"2026-02-04 22:23","pubTimestamp":1770214996,"startTime":"0","endTime":"0","summary":"艾伯维公司高管近日表示，预计到2026年其医美业务增长仍将面临挑战。公司正集中资源通过战略性投资来激活当前渗透率严重不足的市场。\n该高管指出，尽管面临短期增长压力，但医美市场仍存在巨大发展空间。公司将持续投入资金用于市场培育，通过创新营销策略和渠道拓展来挖掘潜在需求。\n目前全球医美市场的渗透水平仍处于低位，这既是挑战也是机遇。艾伯维将把投资重点放在提升市场认知度和可及性上，以期在未来实现业务突破。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2129689514.USD","IE00B2B36J28.USD","LU0122379950.USD","BK4585","IE00BVYPNW00.USD","LU2089984988.USD","LU1003077747.HKD","IE00BSNM7G36.USD","LU0128525929.USD","LU1023059063.AUD","LU0114720955.EUR","LU0417517546.SGD","BK4534","IE00B4R5TH58.HKD","IE00BFTCPJ56.SGD","LU0203345920.USD","LU2089283258.USD","LU0289739699.SGD","LU0234572021.USD","LU0795875086.SGD","LU1057294990.SGD","LU0553294199.USD","LU1162221912.USD","LU2347655156.SGD","LU0310800379.SGD","IE0002270589.USD","LU2023251221.USD","LU0256863902.USD","LU0211328371.USD","LU1551013342.USD","LU0029864427.USD","LU1839511570.USD","LU2237443549.SGD","LU0234570918.USD","SG9999015978.USD","LU0965509101.SGD","LU1551013425.SGD","LU1934455194.USD","SG9999015945.SGD","IE00BLSP4239.USD","ABBV","LU1244550577.SGD","LU0912757837.SGD","LU0820561909.HKD","LU1037948897.HKD","IE00BLSP4452.SGD","LU0738911758.USD","LU0310799852.SGD","LU0965508806.USD","LU2133065610.SGD","LU0661504455.SGD","LU2237443895.HKD","LU0057025933.USD","LU0058720904.USD","BK4581","SG9999015952.SGD","IE0004445239.USD","LU1732800096.USD","LU2112291526.USD","LU0432979614.USD","LU1244550221.USD","LU1496350502.SGD","BK4139","LU0203347892.USD","LU2468319806.SGD","IE00B19Z3581.USD","LU1989771016.USD","SG9999003800.SGD","IE0009355771.USD","LU0289739343.SGD","IE00BDGV0183.EUR","BK4550","LU0511384066.AUD","LU1989772923.USD","LU0256863811.USD","LU0472753341.HKD","BK4559","IE00BJJMRZ35.SGD","LU1267930573.SGD","LU0124676726.USD","LU1061106388.HKD","LU2087621335.USD","LU2237443622.USD","LU0820561818.USD","LU1496350171.SGD","LU1291159041.SGD","LU1989772840.SGD","IE00BJT1NW94.SGD","LU0170899867.USD","LU0943347566.SGD","LU1929549753.HKD","LU0320765646.SGD","LU1718418525.SGD","LU0965509283.SGD","BK4588","BK4566","LU1983299246.USD","SG9999011175.SGD","LU0069063385.USD","LU0211327993.USD","LU0949170772.SGD","LU2129689605.HKD","IE0002141913.USD","LU0985320562.USD","LU0689626769.HKD","LU0689472784.USD","IE00BVYPNV92.GBP","LU2129689431.USD","LU0795875169.SGD","IE00B19Z3B42.SGD","LU1093756325.SGD","LU2237443978.SGD","LU0456855351.SGD","LU0965509010.AUD","LU1934455863.HKD","LU2089284900.SGD","LU0861579265.USD","LU0289961442.SGD","LU0882574055.USD","LU1267930490.SGD","LU1585245621.USD","IE00BN8TJ469.HKD","LU1934455277.USD","LU1093756168.USD","IE00B3PB1722.GBP","LU0158827948.USD","BK4533","LU0198837287.USD","LU1074936037.SGD","LU1037948541.HKD","IE00B42XCP33.USD","LU1430594728.SGD","LU0098860793.USD","LU1732799900.SGD","LU0545039389.USD","IE00BGHQF631.EUR","LU1244550494.USD","SG9999001440.SGD","LU2237443382.USD","LU2237443465.HKD","LU0708994859.HKD","IE00BBT3K403.USD","SG9999015986.USD"],"gpt_icon":0},{"id":"2608362477","title":"医美业务复苏！艾伯维Q4财报超预期，同步上调全年利润指引","url":"https://stock-news.laohu8.com/highlight/detail?id=2608362477","media":"智通财经网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608362477?lang=zh_cn&edition=full","pubTime":"2026-02-04 21:33","pubTimestamp":1770212037,"startTime":"0","endTime":"0","summary":"由于为提振低迷医美业务所做的一系列举措开始见效，艾伯维周三公布了超预期的第四季度业绩，同时上调了2026年盈利指引。","market":"us","thumbnail":"https://static.tigerbbs.com/6a8642475395bb363eacb86148917e7b","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/6a8642475395bb363eacb86148917e7b"],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1401765.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":"医美业务复苏！艾伯维Q4财报超预期，同步上调全年利润指引","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["ABBV"],"gpt_icon":0},{"id":"1151308318","title":"艾伯维第四季度业绩受收购IPR&D及里程碑费用影响 每股收益承压0.71美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1151308318","media":"美股速递","labels":["dataReport","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1151308318?lang=zh_cn&edition=full","pubTime":"2026-02-04 20:49","pubTimestamp":1770209352,"startTime":"0","endTime":"0","summary":"艾伯维最新公布的第四季度财务数据显示，公司当季业绩受到收购相关无形资产研发（IPR&D）及里程碑费用的显著拖累。具体而言，这些一次性支出对每股收益造成了0.71美元的负面影响。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0965509010.AUD","LU1074936037.SGD","LU0882574055.USD","LU2087621335.USD","LU0912757837.SGD","LU1057294990.SGD","LU0234570918.USD","BK4550","LU0310799852.SGD","LU0545039389.USD","LU0553294199.USD","BK4533","BK4559","BK4581","IE00B3PB1722.GBP","LU0122379950.USD","SG9999011175.SGD","LU0456855351.SGD","BK4139","LU0234572021.USD","LU1162221912.USD","LU1989772840.SGD","LU2237443465.HKD","LU0965509101.SGD","IE00B19Z3581.USD","LU0170899867.USD","SG9999015952.SGD","BK4585","LU0211327993.USD","ABBV","LU1037948541.HKD","LU0211328371.USD","LU1093756325.SGD","IE0004445239.USD","LU0861579265.USD","LU1061106388.HKD","LU0472753341.HKD","SG9999015986.USD","LU0114720955.EUR","LU2133065610.SGD","LU0985320562.USD","IE00BBT3K403.USD","LU0417517546.SGD","IE00BSNM7G36.USD","IE00BVYPNW00.USD","LU0320765646.SGD","LU1023059063.AUD","LU1732799900.SGD","LU1839511570.USD","LU0820561909.HKD","LU0128525929.USD","LU1244550494.USD","LU0029864427.USD","LU1551013425.SGD","BK4588","LU0124676726.USD","LU0689472784.USD","LU2468319806.SGD","LU1291159041.SGD","IE0002141913.USD","SG9999015978.USD","LU1496350502.SGD","LU0203345920.USD","SG9999015945.SGD","LU1496350171.SGD","LU0098860793.USD","LU0069063385.USD","IE00B19Z3B42.SGD","LU1929549753.HKD","LU2089984988.USD","IE00BLSP4452.SGD","IE00B42XCP33.USD","LU0738911758.USD","LU1267930490.SGD","LU1934455277.USD","LU0289739699.SGD","LU0310800379.SGD","LU2237443622.USD","IE00BFTCPJ56.SGD","IE00BN8TJ469.HKD","LU0965509283.SGD","LU2237443382.USD","LU0289961442.SGD","LU1983299246.USD","LU2237443978.SGD","LU0943347566.SGD","LU1003077747.HKD","LU0708994859.HKD","LU2089283258.USD","LU0058720904.USD","LU1244550577.SGD","LU1430594728.SGD","LU1585245621.USD","LU0289739343.SGD","LU0158827948.USD","SG9999003800.SGD","IE00B2B36J28.USD","LU1244550221.USD","LU2347655156.SGD","IE00BVYPNV92.GBP","LU0256863902.USD","LU1718418525.SGD","LU2112291526.USD","LU2237443895.HKD","LU1989771016.USD","LU1037948897.HKD","LU2129689514.USD","IE0002270589.USD","LU2237443549.SGD","IE00BLSP4239.USD","IE00BJJMRZ35.SGD","BK4566","LU1732800096.USD","LU0795875169.SGD","LU1934455194.USD","LU2023251221.USD","LU0661504455.SGD","LU0689626769.HKD","IE00B4R5TH58.HKD","LU1093756168.USD","LU1989772923.USD","IE00BJT1NW94.SGD","LU2129689605.HKD","IE0009355771.USD","LU0820561818.USD","LU0256863811.USD","LU0795875086.SGD","BK4534","IE00BGHQF631.EUR","LU0965508806.USD","LU0949170772.SGD","LU0511384066.AUD","LU0057025933.USD","LU0198837287.USD","SG9999001440.SGD","LU1551013342.USD","LU0203347892.USD","LU1934455863.HKD","LU0432979614.USD","IE00BDGV0183.EUR","LU2129689431.USD","LU2089284900.SGD","LU1267930573.SGD"],"gpt_icon":0},{"id":"2608733028","title":"艾伯维(ABBV.US)乌帕替尼新适应症申报上市 或将成为首个用于治疗白癜风的全身性药物","url":"https://stock-news.laohu8.com/highlight/detail?id=2608733028","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608733028?lang=zh_cn&edition=full","pubTime":"2026-02-04 14:48","pubTimestamp":1770187724,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，当地时间2月3日，艾伯维宣布，已向美国 FDA 和欧洲 EMA 提交了乌帕替尼用于治疗成人和青少年非节段型白癜风的新适应症申请。若获得批准，乌帕替尼将成为首个可用于治疗白癜风的全身性药物，以期改变白癜风的治疗格局。此前公布的 Viti-Up 研究结果支持了此次向FDA和EMA提交的监管申请。据悉，乌帕替尼为艾伯维旗下的重磅产品，2024年全球销售额为59.71亿美元，同比增长50.44%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1401479.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"艾伯维(ABBV.US)乌帕替尼新适应症申报上市 或将成为首个用于治疗白癜风的全身性药物","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1023059063.AUD","LU0114720955.EUR","LU2087621335.USD","LU2237443895.HKD","IE00B19Z3581.USD","LU2237443622.USD","LU1061106388.HKD","LU1162221912.USD","LU0882574055.USD","BK4581","LU1551013342.USD","LU0912757837.SGD","IE00BLSP4239.USD","LU0320765646.SGD","LU1718418525.SGD","LU0158827948.USD","LU0738911758.USD","LU0708994859.HKD","LU2089283258.USD","LU0289739699.SGD","LU1093756168.USD","LU1267930573.SGD","SG9999001440.SGD","LU1244550494.USD","LU1732800096.USD","LU2237443549.SGD","SG9999015986.USD","LU0943347566.SGD","LU0256863811.USD","IE00B4R5TH58.HKD","LU0965509283.SGD","BK4566","LU0170899867.USD","BK4534","BK4550","LU0122379950.USD","BK4533","LU0310799852.SGD","LU2129689514.USD","BK4588","IE00BBT3K403.USD","LU1934455277.USD","BK4559","LU2237443465.HKD","IE00B19Z3B42.SGD","LU2237443382.USD","LU1551013425.SGD","ABBV","LU1934455194.USD","LU0965508806.USD"],"gpt_icon":0},{"id":"1155170461","title":"艾伯维向FDA及EMA提交乌帕替尼治疗成人与青少年白癜风的新适应症申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1155170461","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1155170461?lang=zh_cn&edition=full","pubTime":"2026-02-03 21:00","pubTimestamp":1770123615,"startTime":"0","endTime":"0","summary":"艾伯维公司已正式向美国食品药品监督管理局（FDA）及欧洲药品管理局（EMA）提交了乌帕替尼（商品名：Rinvoq®）用于治疗成人与青少年白癜风患者的监管申请。此次提交标志着该JAK抑制剂在拓展自身免疫疾病治疗版图上的重要进展。若获批准，乌帕替尼将成为针对这一慢性皮肤病患者群体的创新治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1551013342.USD","LU0211328371.USD","LU0738911758.USD","LU1839511570.USD","LU0289739699.SGD","IE00BJT1NW94.SGD","LU1093756325.SGD","IE00BLSP4239.USD","LU1732800096.USD","LU2237443382.USD","LU0553294199.USD","IE00B42XCP33.USD","SG9999011175.SGD","SG9999015952.SGD","LU1989772923.USD","IE00BBT3K403.USD","LU0029864427.USD","LU2347655156.SGD","BK4588","LU0417517546.SGD","SG9999015945.SGD","SG9999015986.USD","LU1003077747.HKD","LU0472753341.HKD","IE00BFTCPJ56.SGD","IE00BVYPNW00.USD","IE00B2B36J28.USD","LU0203345920.USD","LU0689472784.USD","IE00BJJMRZ35.SGD","LU1496350171.SGD","LU0965508806.USD","IE00BSNM7G36.USD","LU0943347566.SGD","LU0170899867.USD","LU1934455863.HKD","IE00B3PB1722.GBP","LU0310800379.SGD","LU1244550494.USD","IE0002270589.USD","IE00BVYPNV92.GBP","IE00B19Z3B42.SGD","LU1037948541.HKD","LU2237443549.SGD","LU0256863902.USD","LU1934455277.USD","LU0820561818.USD","LU1037948897.HKD","LU0820561909.HKD","LU0432979614.USD","LU2087621335.USD","SG9999003800.SGD","IE00B19Z3581.USD","LU2133065610.SGD","LU2237443978.SGD","LU1934455194.USD","BK4534","LU2089284900.SGD","LU0912757837.SGD","BK4550","LU1267930573.SGD","LU1989772840.SGD","BK4566","IE00B4R5TH58.HKD","IE00BGHQF631.EUR","LU0211327993.USD","BK4533","IE0004445239.USD","LU0234570918.USD","LU0861579265.USD","LU0949170772.SGD","BK4139","IE00BLSP4452.SGD","LU1244550221.USD","LU1496350502.SGD","LU0661504455.SGD","LU0965509010.AUD","LU0965509283.SGD","LU1074936037.SGD","LU2089283258.USD","LU1267930490.SGD","LU2237443465.HKD","BK4581","LU2129689514.USD","IE00BN8TJ469.HKD","LU0511384066.AUD","LU1732799900.SGD","LU1023059063.AUD","IE0002141913.USD","LU0882574055.USD","LU0122379950.USD","LU1989771016.USD","LU0057025933.USD","LU0234572021.USD","LU0795875169.SGD","LU1551013425.SGD","LU0320765646.SGD","LU0795875086.SGD","LU2237443895.HKD","LU2089984988.USD","LU1244550577.SGD","LU0289739343.SGD","LU0158827948.USD","LU1585245621.USD","LU1061106388.HKD","LU2237443622.USD","LU1162221912.USD","LU1983299246.USD","LU0128525929.USD","LU1057294990.SGD","BK4559","LU1291159041.SGD","IE00BDGV0183.EUR","LU0289961442.SGD","LU0114720955.EUR","ABBV","LU0098860793.USD","LU0689626769.HKD","LU0198837287.USD","SG9999001440.SGD","LU2129689605.HKD","SG9999015978.USD","LU0985320562.USD","LU0965509101.SGD","LU2112291526.USD","LU1093756168.USD","IE0009355771.USD","LU0708994859.HKD","BK4585","LU0058720904.USD","LU1430594728.SGD","LU0256863811.USD","LU0124676726.USD","LU2129689431.USD","LU0069063385.USD","LU1929549753.HKD","LU2468319806.SGD","LU2023251221.USD","LU0310799852.SGD","LU0545039389.USD","LU0456855351.SGD","LU0203347892.USD","LU1718418525.SGD"],"gpt_icon":0},{"id":"2605145750","title":"艾伯维(ABBV.US)利生奇珠单抗新适应症在华获批 用于治疗溃疡性结肠炎","url":"https://stock-news.laohu8.com/highlight/detail?id=2605145750","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605145750?lang=zh_cn&edition=full","pubTime":"2026-01-22 14:31","pubTimestamp":1769063499,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，1月22日，艾伯维宣布利生奇珠单抗在华获批第二项适应症，用于治疗对传统治疗或生物制剂治疗应答不足、失应答或不耐受的中重度活动性溃疡性结肠炎成年患者。IL-23是一种参与炎症过程的细胞因子，被认为与许多慢性免疫介导疾病有关。2025年3月10日，利生奇珠单抗在中国首次获批上市，用于治疗对传统治疗或生物制剂治疗应答不足、失应答或不耐受的中重度活动性克罗恩病成年患者。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1396051.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"艾伯维(ABBV.US)利生奇珠单抗新适应症在华获批 用于治疗溃疡性结肠炎","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1496350171.SGD","LU0912757837.SGD","LU0545039389.USD","IE00BVYPNV92.GBP","LU0795875169.SGD","LU0795875086.SGD","LU0320765646.SGD","LU0689472784.USD","BK4581","BK4566","LU1430594728.SGD","LU0158827948.USD","LU2133065610.SGD","SG9999015952.SGD","LU1057294990.SGD","LU2468319806.SGD","LU0289739343.SGD","LU0965509283.SGD","LU1551013342.USD","LU0310800379.SGD","LU0965509010.AUD","IE00BVYPNW00.USD","LU1496350502.SGD","LU1732800096.USD","SG9999001440.SGD","LU1839511570.USD","IE00BJJMRZ35.SGD","LU0114720955.EUR","LU1074936037.SGD","SG9999011175.SGD","LU1037948541.HKD","LU2237443465.HKD","LU2023251221.USD","LU1003077747.HKD","LU2089283258.USD","LU1718418525.SGD","LU2089984988.USD","LU0965509101.SGD","BK4559","LU2237443895.HKD","LU0708994859.HKD","IE00B19Z3581.USD","LU0058720904.USD","LU1061106388.HKD","BK4550","LU1093756168.USD","ABBV","LU0820561909.HKD","LU0211327993.USD","LU0029864427.USD"],"gpt_icon":0},{"id":"1194878871","title":"艾伯维高管称伊布替尼将面临竞争与价格谈判带来的市场侵蚀——摩根大通医疗会议","url":"https://stock-news.laohu8.com/highlight/detail?id=1194878871","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1194878871?lang=zh_cn&edition=full","pubTime":"2026-01-15 01:16","pubTimestamp":1768410985,"startTime":"0","endTime":"0","summary":"在摩根大通医疗健康大会上，艾伯维公司高管坦言，旗下重磅药物伊布替尼（Imbruvica）未来将因市场竞争加剧及医保价格谈判压力，出现一定程度的市场份额侵蚀。\n这一表态反映出生物医药行业当前面临的共同挑战：明星产品在专利保护期后面临仿制药竞争，同时全球范围内医保控费政策日趋严格，企业需在创新投入与利润平衡间寻求新路径。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1037948897.HKD","LU1244550494.USD","LU1496350171.SGD","SG9999001440.SGD","LU0203345920.USD","LU0545039389.USD","LU0795875086.SGD","LU0795875169.SGD","LU1093756325.SGD","LU2087621335.USD","LU1430594728.SGD","LU1267930490.SGD","IE00B19Z3581.USD","IE00BN8TJ469.HKD","LU0122379950.USD","LU1989772923.USD","IE00B3PB1722.GBP","LU0158827948.USD","IE00BDGV0183.EUR","LU0211328371.USD","IE0002270589.USD","LU1037948541.HKD","LU0289961442.SGD","IE00BLSP4239.USD","LU0198837287.USD","LU2237443549.SGD","LU0965508806.USD","LU0820561909.HKD","IE00B19Z3B42.SGD","LU0124676726.USD","ABBV","BK4585","IE00BLSP4452.SGD","LU1291159041.SGD","LU0417517546.SGD","LU0820561818.USD","SG9999011175.SGD","LU0708994859.HKD","LU0861579265.USD","IE00B42XCP33.USD","LU0289739343.SGD","LU2089984988.USD","LU1023059063.AUD","LU0511384066.AUD","LU2089284900.SGD","LU1057294990.SGD","LU2089283258.USD","LU1244550221.USD","LU0310800379.SGD","BK4588","IE0009355771.USD","LU2129689514.USD","LU0949170772.SGD","SG9999015952.SGD","LU1934455277.USD","LU2023251221.USD","LU0456855351.SGD","BK4581","LU1585245621.USD","LU0058720904.USD","LU1989772840.SGD","IE00B4R5TH58.HKD","LU0965509101.SGD","LU2237443465.HKD","LU1732799900.SGD","BK4533","BK4566","LU2237443382.USD","SG9999003800.SGD","LU0256863902.USD","LU1989771016.USD","LU1074936037.SGD","LU0057025933.USD","LU0289739699.SGD","LU0069063385.USD","LU0912757837.SGD","LU2237443622.USD","IE00BJT1NW94.SGD","LU2468319806.SGD","LU0943347566.SGD","IE00BGHQF631.EUR","LU0170899867.USD","LU2129689431.USD","IE00B2B36J28.USD","LU1929549753.HKD","IE0002141913.USD","LU0256863811.USD","LU2112291526.USD","LU0689626769.HKD","LU2237443895.HKD","IE00BVYPNW00.USD","LU0661504455.SGD","LU1061106388.HKD","LU0965509010.AUD","LU1551013342.USD","LU2347655156.SGD","LU2237443978.SGD","LU1934455863.HKD","IE00BBT3K403.USD","LU0472753341.HKD","LU1267930573.SGD","BK4550","LU0553294199.USD","LU0114720955.EUR","LU0985320562.USD","LU1732800096.USD","SG9999015986.USD","LU1934455194.USD","LU0689472784.USD","SG9999015945.SGD","LU0310799852.SGD","LU0211327993.USD","LU1093756168.USD","LU0432979614.USD","IE00BJJMRZ35.SGD","SG9999015978.USD","IE00BVYPNV92.GBP","BK4559","IE00BSNM7G36.USD","LU1244550577.SGD","BK4534","IE00BFTCPJ56.SGD","LU0128525929.USD","LU0882574055.USD","LU2133065610.SGD","LU1162221912.USD","LU1551013425.SGD","LU0098860793.USD","LU0203347892.USD","LU0029864427.USD","LU0965509283.SGD","LU1718418525.SGD","LU0234570918.USD","LU1983299246.USD","LU0320765646.SGD","LU0738911758.USD","LU1003077747.HKD","LU1496350502.SGD","LU1839511570.USD","LU0234572021.USD","IE0004445239.USD","LU2129689605.HKD","BK4139"],"gpt_icon":0},{"id":"1192910344","title":"艾伯维承诺在美投资千亿美元 以换取关税豁免","url":"https://stock-news.laohu8.com/highlight/detail?id=1192910344","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1192910344?lang=zh_cn&edition=full","pubTime":"2026-01-13 11:49","pubTimestamp":1768276177,"startTime":"0","endTime":"0","summary":"艾伯维近日与美国政府签署协议，承诺下调部分药品价格并在美本土投资1000亿美元，以换取特定关税豁免资格。艾伯维在周一发布的声明中表示，本次签署的协议全面响应了上述四项要求。根据协议，未来十年内，艾伯维将把这1000亿美元投向美国本土的研发领域及资本开支项目，其中涵盖药品生产制造环节。作为交换条件，艾伯维将获得关税豁免资格，同时免于受到未来药品定价强制政策的约束。","market":"us","thumbnail":"https://static.tigerbbs.com/819399b2009bd809953aeb10f7e13fae","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/819399b2009bd809953aeb10f7e13fae"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/content/detail/1392071.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["ABBV"],"gpt_icon":0},{"id":"2603579765","title":"艾伯维(ABBV.US)承诺在美投资千亿美元 以换取关税豁免","url":"https://stock-news.laohu8.com/highlight/detail?id=2603579765","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603579765?lang=zh_cn&edition=full","pubTime":"2026-01-13 11:26","pubTimestamp":1768274813,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，艾伯维近日与美国政府签署协议，承诺下调部分药品价格并在美本土投资1000亿美元，以换取特定关税豁免资格。艾伯维在周一发布的声明中表示，本次签署的协议全面响应了上述四项要求。根据协议，未来十年内，艾伯维将把这1000亿美元投向美国本土的研发领域及资本开支项目，其中涵盖药品生产制造环节。作为交换条件，艾伯维将获得关税豁免资格，同时免于受到未来药品定价强制政策的约束。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1392071.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0965509010.AUD","LU1074936037.SGD","LU2237443549.SGD","IE00BLSP4239.USD","LU2237443622.USD","LU0912757837.SGD","LU1732800096.USD","IE00BFTCPJ56.SGD","IE00BN8TJ469.HKD","LU0965509283.SGD","LU1057294990.SGD","LU2237443978.SGD","IE00BBT3K403.USD","LU0661504455.SGD","LU0310799852.SGD","IE00BSNM7G36.USD","LU1003077747.HKD","LU1023059063.AUD","LU1732799900.SGD","BK4533","LU1093756168.USD","LU0456855351.SGD","LU0256863811.USD","LU0689472784.USD","LU1244550577.SGD","LU2468319806.SGD","SG9999015978.USD","LU1162221912.USD","LU0965509101.SGD","SG9999015945.SGD","LU1496350171.SGD","LU0158827948.USD","LU0098860793.USD","LU2347655156.SGD","LU0198837287.USD","IE00BVYPNV92.GBP","LU0211327993.USD","LU1551013342.USD","LU1718418525.SGD","LU1934455863.HKD","ABBV","LU2112291526.USD","LU1037948541.HKD","LU0211328371.USD","LU1037948897.HKD","LU2089984988.USD","LU2129689431.USD","LU2089284900.SGD","LU1267930573.SGD","IE00B42XCP33.USD"],"gpt_icon":0},{"id":"1107664320","title":"艾伯维公司未来十年将斥资1000亿美元投入美国研发及资本开支，涵盖制造业","url":"https://stock-news.laohu8.com/highlight/detail?id=1107664320","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1107664320?lang=zh_cn&edition=full","pubTime":"2026-01-13 07:32","pubTimestamp":1768260770,"startTime":"0","endTime":"0","summary":"艾伯维公司宣布，将在未来十年内于美国市场投入高达1000亿美元的资金，重点投向研发活动以及资本性支出，其中制造业相关投资亦被纳入这一庞大计划。这一战略部署彰显了公司对强化本土创新能力和生产基础设施的长期承诺。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0820561909.HKD","LU1934455194.USD","LU1244550577.SGD","IE00BN8TJ469.HKD","IE00BVYPNV92.GBP","LU0122379950.USD","ABBV","IE00BBT3K403.USD","LU1934455863.HKD","LU1989771016.USD","LU0211328371.USD","LU0310800379.SGD","LU1934455277.USD","LU2089984988.USD","SG9999015945.SGD","LU2237443549.SGD","IE00BVYPNW00.USD","IE00B4R5TH58.HKD","LU0289739699.SGD","IE0009355771.USD","LU2112291526.USD","IE00BJJMRZ35.SGD","LU0553294199.USD","IE0002141913.USD","BK4566","IE00BJT1NW94.SGD","LU0114720955.EUR","BK4550","IE00BSNM7G36.USD","LU0456855351.SGD","BK4139","IE00BGHQF631.EUR","LU1093756325.SGD","LU1162221912.USD","LU0912757837.SGD","LU0689472784.USD","LU0689626769.HKD","LU2237443622.USD","LU1244550494.USD","LU2237443382.USD","LU0124676726.USD","LU2129689514.USD","LU1732800096.USD","LU0211327993.USD","LU1585245621.USD","LU2237443978.SGD","LU2237443465.HKD","LU0965508806.USD","LU0795875169.SGD","LU1430594728.SGD","LU0708994859.HKD","IE00B42XCP33.USD","LU1267930573.SGD","LU2347655156.SGD","IE00BLSP4239.USD","LU0058720904.USD","LU0234570918.USD","LU2133065610.SGD","LU0661504455.SGD","LU0861579265.USD","LU0098860793.USD","LU1291159041.SGD","IE00BDGV0183.EUR","LU2468319806.SGD","LU1989772923.USD","LU0943347566.SGD","LU0203345920.USD","SG9999015986.USD","IE00B19Z3581.USD","LU0310799852.SGD","LU0128525929.USD","LU0795875086.SGD","SG9999003800.SGD","LU0320765646.SGD","BK4581","LU1003077747.HKD","LU2023251221.USD","LU0965509101.SGD","IE0002270589.USD","BK4588","LU1057294990.SGD","LU1244550221.USD","LU1929549753.HKD","LU0256863902.USD","LU0949170772.SGD","LU0882574055.USD","BK4585","LU1023059063.AUD","LU2087621335.USD","LU2129689605.HKD","IE00BFTCPJ56.SGD","SG9999001440.SGD","LU1983299246.USD","LU1989772840.SGD","LU0256863811.USD","LU1732799900.SGD","LU0158827948.USD","LU1551013425.SGD","BK4533","LU2129689431.USD","SG9999011175.SGD","IE00BLSP4452.SGD","LU1061106388.HKD","IE00B3PB1722.GBP","LU1074936037.SGD","LU0738911758.USD","LU2089283258.USD","LU1496350502.SGD","LU0029864427.USD","LU1839511570.USD","LU0170899867.USD","LU1037948897.HKD","BK4534","SG9999015952.SGD","IE00B19Z3B42.SGD","LU0965509010.AUD","LU1718418525.SGD","LU2237443895.HKD","LU1037948541.HKD","SG9999015978.USD","LU0234572021.USD","LU1496350171.SGD","LU0965509283.SGD","LU1093756168.USD","LU0985320562.USD","IE0004445239.USD","LU1267930490.SGD","LU0820561818.USD","LU0417517546.SGD","LU0203347892.USD","LU0198837287.USD","LU0545039389.USD","LU1551013342.USD","IE00B2B36J28.USD","LU2089284900.SGD","BK4559","LU0432979614.USD"],"gpt_icon":0},{"id":"1156023584","title":"艾伯维公司：将通过Trumprx平台为医疗补助计划提供低价药品，并扩大面向患者的可负担直接治疗方案","url":"https://stock-news.laohu8.com/highlight/detail?id=1156023584","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1156023584?lang=zh_cn&edition=full","pubTime":"2026-01-13 07:32","pubTimestamp":1768260766,"startTime":"0","endTime":"0","summary":"艾伯维公司宣布，将通过其Trumprx平台为医疗补助计划参与者提供低价药品，同时扩大面向患者的可负担直接治疗方案。这一举措旨在提升药品可及性，让更多患者能够以合理价格获得所需治疗。\n通过Trumprx平台，艾伯维将优化药品供应流程，实现从药企到患者的直接服务模式。该战略不仅涵盖价格优惠，还将简化购药流程，为医疗补助计划受益者及自费患者提供更便捷的用药体验。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1839511570.USD","LU2237443895.HKD","LU0114720955.EUR","SG9999001440.SGD","LU2112291526.USD","LU0198837287.USD","LU0256863902.USD","LU1074936037.SGD","LU0965508806.USD","IE00BFTCPJ56.SGD","LU0545039389.USD","BK4550","LU1267930573.SGD","LU1551013342.USD","LU1585245621.USD","LU0820561818.USD","IE00B42XCP33.USD","LU1989772923.USD","LU0211328371.USD","LU0234570918.USD","IE00BVYPNW00.USD","LU0122379950.USD","LU0820561909.HKD","LU0058720904.USD","LU0965509010.AUD","BK4585","BK4559","IE00BGHQF631.EUR","LU1934455863.HKD","LU0211327993.USD","IE0002270589.USD","LU1496350502.SGD","IE00B2B36J28.USD","IE00BBT3K403.USD","LU2237443465.HKD","LU0203347892.USD","IE0002141913.USD","LU0965509283.SGD","LU2089984988.USD","LU2089283258.USD","SG9999015986.USD","IE0004445239.USD","LU0128525929.USD","LU0949170772.SGD","LU0985320562.USD","LU1551013425.SGD","LU2023251221.USD","LU1023059063.AUD","IE00B19Z3B42.SGD","LU0861579265.USD","LU0256863811.USD","LU1934455194.USD","IE00BDGV0183.EUR","LU1037948541.HKD","LU0158827948.USD","IE0009355771.USD","LU1093756325.SGD","LU0795875086.SGD","BK4534","SG9999015952.SGD","LU0553294199.USD","LU0708994859.HKD","BK4566","LU0310800379.SGD","LU0320765646.SGD","LU2237443549.SGD","IE00BVYPNV92.GBP","LU0170899867.USD","LU1244550221.USD","LU0943347566.SGD","LU0882574055.USD","LU1989771016.USD","SG9999003800.SGD","LU2089284900.SGD","LU2129689514.USD","IE00BLSP4452.SGD","LU1037948897.HKD","LU0289739699.SGD","LU2087621335.USD","LU1244550494.USD","IE00B4R5TH58.HKD","BK4139","LU0310799852.SGD","LU1267930490.SGD","SG9999015978.USD","LU2468319806.SGD","LU0124676726.USD","LU1244550577.SGD","LU0738911758.USD","IE00B3PB1722.GBP","LU0432979614.USD","LU0098860793.USD","LU2237443978.SGD","LU1093756168.USD","LU1732799900.SGD","LU1732800096.USD","LU1983299246.USD","LU0912757837.SGD","LU0417517546.SGD","LU0689626769.HKD","LU1496350171.SGD","LU0234572021.USD","SG9999015945.SGD","LU2133065610.SGD","BK4533","LU2237443382.USD","LU1718418525.SGD","LU1003077747.HKD","LU0203345920.USD","LU1291159041.SGD","LU0795875169.SGD","LU1162221912.USD","IE00BLSP4239.USD","LU0965509101.SGD","LU1929549753.HKD","IE00B19Z3581.USD","LU1934455277.USD","IE00BJJMRZ35.SGD","LU0689472784.USD","LU1057294990.SGD","LU2129689431.USD","LU1989772840.SGD","LU0661504455.SGD","LU2237443622.USD","BK4581","BK4588","LU1430594728.SGD","IE00BN8TJ469.HKD","ABBV","LU1061106388.HKD","LU2347655156.SGD","LU2129689605.HKD","IE00BJT1NW94.SGD","LU0029864427.USD","SG9999011175.SGD","LU0456855351.SGD","IE00BSNM7G36.USD"],"gpt_icon":0},{"id":"1107559382","title":"艾伯维与荣昌生物达成协议 后者有望获得高达49.5亿美元里程碑款项","url":"https://stock-news.laohu8.com/highlight/detail?id=1107559382","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1107559382?lang=zh_cn&edition=full","pubTime":"2026-01-12 20:33","pubTimestamp":1768221217,"startTime":"0","endTime":"0","summary":"根据最新合作协议，荣昌生物（Remegen）有资格从艾伯维（AbbVie）获得累计最高达49.5亿美元的款项。这笔巨额资金将涵盖药物研发、监管审批及商业化等多个阶段的里程碑奖励。\n该合作凸显了国际制药巨头对中国生物科技企业创新能力的认可。分段式的付款机制既保障了研发进程的可控性，也为双方创造了共赢的商业前景。随着合作项目的推进，荣昌生物有望通过达成特定技术指标和销售目标激活相应阶段的付款。\n此次交易金额创下中国生物科技企业对外授权合作的新纪录，预示着国内创新药企在全球医药产业链中的地位正在快速提升。双方未透露具体适应症细节，但市场预期该合作可能涉及肿瘤或自身免疫疾病领域的前沿疗法。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0198837287.USD","LU1267930490.SGD","LU0098860793.USD","IE00BJJMRZ35.SGD","SG9999011175.SGD","BK4534","LU2023251221.USD","LU0211327993.USD","LU1057294990.SGD","LU0029864427.USD","LU2347655156.SGD","LU0114720955.EUR","LU0965509101.SGD","IE0004445239.USD","LU0820561909.HKD","BK4550","LU0310800379.SGD","LU1989771016.USD","IE00B2B36J28.USD","LU1732799900.SGD","IE00BFTCPJ56.SGD","LU1244550494.USD","LU1267930573.SGD","LU0965509283.SGD","LU0965508806.USD","IE00B3PB1722.GBP","LU1074936037.SGD","LU2129689605.HKD","IE00BBT3K403.USD","LU0661504455.SGD","LU0256863902.USD","LU2087621335.USD","LU0417517546.SGD","LU0170899867.USD","LU0211328371.USD","LU0256863811.USD","BK4585","SG9999015952.SGD","IE00B42XCP33.USD","688331","LU2237443382.USD","LU1496350502.SGD","IE00BGHQF631.EUR","LU1934455863.HKD","LU0708994859.HKD","LU0965509010.AUD","IE00B19Z3581.USD","LU1989772840.SGD","LU1732800096.USD","LU1934455194.USD","BK4566","LU0234572021.USD","LU1430594728.SGD","LU2129689514.USD","LU1061106388.HKD","LU1983299246.USD","LU0158827948.USD","LU0689626769.HKD","IE0002141913.USD","LU1037948897.HKD","LU2237443549.SGD","LU1929549753.HKD","LU0310799852.SGD","LU2237443622.USD","LU0553294199.USD","LU2112291526.USD","LU0795875169.SGD","IE00BSNM7G36.USD","LU2237443465.HKD","LU0738911758.USD","LU1037948541.HKD","LU1585245621.USD","LU2129689431.USD","IE00B4R5TH58.HKD","LU0432979614.USD","IE00BLSP4239.USD","LU2133065610.SGD","LU0320765646.SGD","BK4588","LU2089283258.USD","LU2237443895.HKD","LU0882574055.USD","LU2237443978.SGD","BK4139","IE00BVYPNW00.USD","SG9999003800.SGD","IE00BDGV0183.EUR","LU1551013342.USD","LU0234570918.USD","SG9999015945.SGD","LU0943347566.SGD","LU1093756325.SGD","IE0002270589.USD","LU2089984988.USD","LU0456855351.SGD","LU0949170772.SGD","LU2468319806.SGD","LU0861579265.USD","LU0203345920.USD","LU1023059063.AUD","SG9999001440.SGD","LU0122379950.USD","LU1244550221.USD","BK4533","ABBV","LU0124676726.USD","LU0203347892.USD","LU0689472784.USD","LU1003077747.HKD","LU0912757837.SGD","BK4581","LU0545039389.USD","LU1064131003.USD","LU1839511570.USD","LU0289739699.SGD","LU2148510915.USD","LU1162221912.USD","BK0239","LU1244550577.SGD","LU1291159041.SGD","IE00BVYPNV92.GBP","IE00B19Z3B42.SGD","LU0820561818.USD","LU2488822045.USD","LU1718418525.SGD","LU1496350171.SGD","LU0795875086.SGD","LU1934455277.USD","IE0009355771.USD","LU1093756168.USD","SG9999015978.USD","LU1551013425.SGD","IE00BN8TJ469.HKD","LU0058720904.USD","LU0985320562.USD","LU1989772923.USD","LU2089284900.SGD","SG9999015986.USD","IE00BLSP4452.SGD","LU1064130708.USD","LU0128525929.USD","IE00BJT1NW94.SGD","BK4559"],"gpt_icon":0},{"id":"1140361953","title":"艾伯维收购亚利桑那州生产设施，持续强化美国本土制造能力","url":"https://stock-news.laohu8.com/highlight/detail?id=1140361953","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1140361953?lang=zh_cn&edition=full","pubTime":"2026-01-12 19:01","pubTimestamp":1768215713,"startTime":"0","endTime":"0","summary":"艾伯维公司近日宣布，将收购位于亚利桑那州的一处生产设施。这一战略举措旨在进一步增强其在美国本土的制造实力，为未来的产品供应提供有力保障。收购完成后，该设施将整合进艾伯维现有的生产网络，提升其在关键治疗领域的产能与灵活性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0985320562.USD","BK4566","LU1093756168.USD","IE00BJJMRZ35.SGD","LU1267930573.SGD","LU0820561909.HKD","LU1551013342.USD","IE00BFXG0V08.USD","LU1244550221.USD","LU0114720955.EUR","LU2089984988.USD","LU0943347566.SGD","LU0965508806.USD","IE00B42XCP33.USD","IE00BSNM7G36.USD","LU0256863811.USD","LU0456855351.SGD","LU0738911758.USD","LU2237443465.HKD","LU0689472784.USD","ABBV","LU0170899867.USD","LU2112291526.USD","BK4121","LU2237443978.SGD","LU1023059063.AUD","LU1732800096.USD","BK4504","BK4550","BK4581","IE00BVYPNW00.USD","LU0310800379.SGD","LU0234572021.USD","LU0795875169.SGD","LU1496350502.SGD","LU1093756325.SGD","LU0912757837.SGD","IE0009355771.USD","LU0965509101.SGD","SG9999015945.SGD","IE00B19Z3581.USD","LU0949170772.SGD","LU2468319806.SGD","LU0345774631.USD","IE00BGHQF631.EUR","LU1061106388.HKD","BK4534","LU1291159041.SGD","BK4139","IE00BVYPNV92.GBP","SG9999015952.SGD","LU1934455277.USD","IE00B4R5TH58.HKD","LU1551013425.SGD","SG9999003800.SGD","IE00BJT1NW94.SGD","LU0128525929.USD","IE00BFTCPJ56.SGD","IE0002141913.USD","IE00BYQQ9H92.USD","IE00B2B36J28.USD","IE00B3PB1722.GBP","BK4567","LU2237443895.HKD","IE00BLSP4239.USD","LU0882574055.USD","WST","LU0098860793.USD","LU1267930490.SGD","BK4533","LU2089284900.SGD","LU1929549753.HKD","LU1162221912.USD","BK4559","IE00BN8TJ469.HKD","LU0708994859.HKD","LU1496350171.SGD","IE00BLSP4452.SGD","LU0198837287.USD","LU0689626769.HKD","LU1718418525.SGD","SG9999015986.USD","LU0029864427.USD","LU0122379950.USD","LU0861579265.USD","LU0310799852.SGD","SG9999015978.USD","LU0106261612.USD","LU0345774391.USD","LU0820561818.USD","LU1244550577.SGD","LU0012050646.USD","LU0661504455.SGD","LU0795875086.SGD","LU0124676726.USD","LU1585245621.USD","LU2237443622.USD","LU0203345920.USD","LU2089283258.USD","LU1989772923.USD","LU2347655156.SGD","LU0234570918.USD","LU1003077747.HKD","LU0965509283.SGD","IE00BDGV0183.EUR","LU1839511570.USD","LU1037948897.HKD","LU1074936037.SGD","LU0320765646.SGD","LU1732799900.SGD","LU0058720904.USD","LU0432979614.USD","BK4588","BK4585","LU0211327993.USD","LU1430594728.SGD","LU2237443382.USD","LU2237443549.SGD","LU0211328371.USD","IE00B19Z3B42.SGD","LU1037948541.HKD","LU2129689431.USD","LU1057294990.SGD","LU1989772840.SGD","LU2129689605.HKD","LU0289739699.SGD","LU1934455194.USD","LU0545039389.USD","LU1989771016.USD","LU2133065610.SGD","LU0965509010.AUD","LU1983299246.USD","LU0553294199.USD","IE00B64QTZ34.USD","LU1244550494.USD","LU0256863902.USD","LU0203347892.USD","LU2129689514.USD","SG9999001440.SGD","LU2087621335.USD","IE0004445239.USD","LU2023251221.USD","SG9999011175.SGD","IE00BBT3K403.USD","LU1934455863.HKD","LU0417517546.SGD","LU0158827948.USD","IE0002270589.USD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.abbvie.com","stockEarnings":[{"period":"1week","weight":0.0361},{"period":"1month","weight":0.0433},{"period":"3month","weight":-0.0037},{"period":"6month","weight":0.12},{"period":"1year","weight":0.1967},{"period":"ytd","weight":0.0132}],"compareEarnings":[{"period":"1week","weight":-0.0128},{"period":"1month","weight":-0.0125},{"period":"3month","weight":0.0146},{"period":"6month","weight":0.0595},{"period":"1year","weight":0.1181},{"period":"ytd","weight":-0.0002}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"艾伯维公司注册成立于2012年4月10日，是一家全球性的、以研究为基础的生物制药公司。Abbvie公司从事开发和销售先进的疗法，来解决一些世界上最复杂和严重的疾病。Abbvie公司的产品主要集中在慢性自身免疫性疾病领域，包括类风湿性关节炎，牛皮癣和克罗恩病，银屑病和克罗恩病;低睾酮，HIV，子宫内膜异位症;甲状腺疾病;帕金森病;和并发症的慢性肾脏疾病和囊性纤维化相关的或其他健康问题。","yearOnYearQuotes":[{"month":1,"riseRate":0.357143,"avgChangeRate":-0.019222},{"month":2,"riseRate":0.857143,"avgChangeRate":0.038896},{"month":3,"riseRate":0.769231,"avgChangeRate":0.006022},{"month":4,"riseRate":0.615385,"avgChangeRate":0.009221},{"month":5,"riseRate":0.615385,"avgChangeRate":0.002163},{"month":6,"riseRate":0.461538,"avgChangeRate":0.008788},{"month":7,"riseRate":0.538462,"avgChangeRate":0.01232},{"month":8,"riseRate":0.538462,"avgChangeRate":0.007409},{"month":9,"riseRate":0.538462,"avgChangeRate":0.014941},{"month":10,"riseRate":0.615385,"avgChangeRate":0.007438},{"month":11,"riseRate":0.769231,"avgChangeRate":0.063841},{"month":12,"riseRate":0.692308,"avgChangeRate":0.025718}],"exchange":"NYSE","name":"艾伯维公司","nameEN":"AbbVie"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"艾伯维公司(ABBV)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供艾伯维公司(ABBV)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"艾伯维公司,ABBV,艾伯维公司股票,艾伯维公司股票老虎,艾伯维公司股票老虎国际,艾伯维公司行情,艾伯维公司股票行情,艾伯维公司股价,艾伯维公司股市,艾伯维公司股票价格,艾伯维公司股票交易,艾伯维公司股票购买,艾伯维公司股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"艾伯维公司(ABBV)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供艾伯维公司(ABBV)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}